Sab Biotherapeutics, Inc. (SABS) Stock Price & Analysis

Sab Biotherapeutics, Inc. (SABS) rose 0.00% to USD 3.72 as of September 8, 2026 at 06:55 UTC, according to Nexqual real-time market data.

SABS last closed at USD 3.72; the session ranged USD 3.7–3.75 on volume of 110,633 shares. Market capitalization is —, with a 52-week range of USD 1.85–5.15 (NCM). Source: Nexqual, September 8, 2026 at 06:55 UTC.

Key Statistics (as of September 8, 2026 at 06:55 UTC)

Technical Analysis (SABS)

Nexqual's technical model rates SABS "SELL" based on 1 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 06:55 UTC.

From Sab Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)

Key Strengths & Strategy (as disclosed to the SEC)

• Proprietary Production Platform Overview Our proprietary production platform gives us the unique ability to generate targeted, hIgG without the need for human donors or plasma.
• Using advanced genetic engineering and antibody science, we developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma.
• Our proprietary platform holds the potential to generate additional novel therapeutic candidates to expand our pipeline, utilizing the human immune response to generate the optimal repertoire of hIgG for drug targets of interest.
• SAFEGUARD, the Company's multicenter, global, randomized, double-blind, placebo-controlled Phase 2b clinical trial, is designed and powered as a registrational program across multiple regions, including the United States, EMA-member states, the United Kingdom, Australia, and New Zealand.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:55 UTC. This page is informational and not investment advice.